30 Mar 2020
Following a substantial increase in the price of an anti-epilepsy drug, the UK Competition and Markets Authority (CMA) fined Pfizer and Flynn Pharma nearly £90 million for unfair prices charged to the NHS.
But in June 2018 the Competition Appeal Tribunal (CAT) set aside the CMA’s decision and biggest ever fine and in March 2020 the Court of Appeal largely upheld the CAT judgment, quashing the fines and referring the case back to the CMA. Is this the end of the road for excessive pricing cases?
This material is provided for general information only. It does not constitute legal or other professional advice.
Are you sure want to delete comment ?
Scan this QR Code to share this content
